Sugi Predict

Sugi Predict / Compounds / SCHEMBL1887153

SCHEMBL1887153

SCHEMBL1887153

O=C(O)c1ccc(Nc2ccncc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAPRT Q6XQN6 1/20 0.64
▸ CAMK2D Q13557 1/20 0.58
▸ POLB P06746 2/20 0.57
▸ MAPT P10636 2/20 0.57
▸ NPC1 O15118 2/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ GAA P10253 2/20 0.56
▸ NAMPT P43490 1/20 0.54
▸ ABCB1 P08183 1/20 0.54
▸ ABCG2 Q9UNQ0 1/20 0.54
▸ KDM4E B2RXH2 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ AURKA O14965 2/20 0.53
▸ RAD52 P43351 1/20 0.52
▸ MITF O75030 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ GSK3A P49840 1/20 0.50
▸ GSK3B P49841 1/20 0.50
▸ TP53 P04637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27193253 0.89 POLB (0.74) POLBMAPTGAANAMPTKDM4E
SCHEMBL251773 0.87 TSHR (0.67) NAPRTMAPTNPC1RAB9AGAA
SCHEMBL10836457 0.82 POLB (0.60) POLBMAPTGAAKDM4EL3MBTL1
4-Phenylamino Benzoic Acid SCHEMBL70190 0.80 MAPK13 (0.72) NAPRTPOLBMAPTGAAKDM4E
SCHEMBL9479471 0.80 MAPK13 (0.72) NAPRTPOLBMAPTGAAKDM4E
SCHEMBL23999623 0.80 KDM4E (0.85) POLBMAPTNPC1RAB9AGAA
SCHEMBL30828582 0.80 KDM4E (0.85) POLBMAPTNPC1RAB9AGAA
SCHEMBL27193275 0.80 KDM4E (0.85) NAPRTPOLBMAPTGAANAMPT
SCHEMBL4872573 0.80 HCAR2 (0.54) NAPRTNPC1RAB9AGAAAURKA
SCHEMBL30828552 0.80 KDM4E (0.85) POLBMAPTNPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 — — US disclosed
WO-2023081812-A2 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed
WO-2014072903-A1 NOVEL AMINOMETHYL-PHENOL DERIVATIVES AS ANTIMALARIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2014-05-15 — — WO disclosed
US-20110256092-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2011-10-20 — — US disclosed
US-20110256092-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2011-10-20 — — US disclosed
US-20080175814-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2008-07-24 — — US disclosed
US-20080175814-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2008-07-24 — — US disclosed
WO-2008046085-A2 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION SUPERGEN, INC. (US) 2008-04-17 — — WO disclosed
WO-2007075688-A2 SUBSTITUTED ANILINE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS SCHERING CORPORATION (US) 2007-07-05 — — WO disclosed
US-20070142394-A1 Substituted aniline derivatives useful as histamine H3 antagonists SCHERING CORPORATION 2007-06-21 — — US disclosed
US-20070142394-A1 Substituted aniline derivatives useful as histamine H3 antagonists SCHERING CORPORATION 2007-06-21 — — US disclosed
US-20070066586-A1 ANILINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2007-03-22 — — US disclosed
US-20070066586-A1 ANILINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2007-03-22 — — US disclosed
US-4610991-A Antihypertensive pyridylaminobenzamide compounds STERLING DRUG INC. (US) 1986-09-09 — — US disclosed
EP-0098951-A2 Aminobenzamide derivatives and preparation thereof STERLING DRUG INC. (US) 1984-01-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR NAPRT 2838/4885CAMK2D 547/4885POLB 2552/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR NAPRT 2913/4885CAMK2D 548/4885POLB 2609/4885
US-20070142394-A1 Substituted aniline derivatives useful as histamine H3 antagonists HRH3, CHRM2, HCRTR2 NAPRT 3026/4885CAMK2D 2751/4885POLB 3925/4885
US-20080175814-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION DNMT1, DNMT3A, DNMT3L NAPRT 1025/4885CAMK2D 1136/4885POLB 187/4885
US-20110256092-A1 QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION DNMT1, DNMT3A, DNMT3L NAPRT 1025/4885CAMK2D 1136/4885POLB 187/4885
US-20070066586-A1 ANILINE DERIVATIVES SERPINB1, ACE, REN NAPRT 1376/4885CAMK2D 3764/4885POLB 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.